Truly, the described clinical scenario1 had its origins in 1999 with the discovery and ongoing characterization of IL-18 binding protein (IL-18BP) by Novick et al.2 We are grateful for their correspondence detailing the salient properties of this molecule.3 Regrettably, our original article was unable to include such details due to space limitations and the need to provide sufficient detail on the clinical scenario presented. We obviously agree that this molecule is well suited to the task of therapeutically blocking IL-18.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qodmrq
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
by Demin Li, Carol Bentley, Jenna Yates, Maryam Salimi, Jenny Greig, Sarah Wiblin, Tasneem Hassanali, Alison H. Banham Therapeutic monoclon...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nL9dMr via IFTTT
-
Summary We tested whether prophylactic droperidol and ondansetron, in combination with a moderate dose of dexamethasone, were equally effe...
-
Background Although pneumonia is a leading cause of death in New York City (NYC), limited data exist about the settings in which pneumonia ...
-
Web version of a book about Subversion. Work in progress, however already very complete. The book should be published by O'Reilly and As...
-
Abstract Background Head and neck extirpations requiring reconstruction are challenging surgeries with high postoperative complication r...
-
ACS Nano DOI: 10.1021/acsnano.6b08567 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oNpdhD via...
-
by Kerstin Jost, Isabelle Pramana, Edgar Delgado-Eckert, Nitin Kumar, Alexandre N. Datta, Urs Frey, Sven M. Schulzke Background Poor contro...
-
Vol.30 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nItCSB via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου